Abstract
Recent studies have demonstrated an association of glucagon-like peptide-1(GLP-1)signaling defect with non-alcoholic fatty liver disease(NAFLD). Native GLP-1 and GLP-1-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells. Moreover, GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD. (Chin J Endocrinol Metab, 2015, 31: 386-389) Key words: Non-alcoholic fatty liver disease; Glucagon-like peptide-1; Dipeptidyl peptidase-4
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
